Curated News
By: NewsRamp Editorial Staff
December 02, 2025
Oncotelic's Nano Platform Shows Versatility in Delivering Complex Cancer Drugs
TLDR
- Oncotelic's Deciparticle platform offers a competitive edge by enabling rapid development of diverse cancer drugs with cGMP-ready manufacturing for faster clinical translation.
- The Deciparticle platform formulates hydrophobic therapeutics into sub-20 nm nanoparticles using ISO-5 manufacturing, creating a versatile delivery system for multiple drug candidates.
- This technology advances cancer treatment by improving drug delivery for high-unmet-need cancers and rare pediatric diseases, potentially saving lives and reducing suffering.
- Oncotelic's nanomedicine platform can package diverse compounds like macrolides and peptides into tiny nanoparticles, showcasing innovative drug delivery science for oncology and immunology.
Impact - Why it Matters
This development matters because it addresses a critical bottleneck in modern drug development: delivering complex, often insoluble, therapeutic molecules effectively to their target in the body. Many promising drug candidates fail not because they lack biological activity, but because they cannot be formulated into a stable, deliverable form. The Deciparticle platform's ability to consistently package diverse hydrophobic compounds into tiny, IV-ready nanoparticles could unlock a new wave of treatments for cancers and other diseases. For patients, this translates to potential access to more effective therapies that were previously stuck in the lab. For the biopharma industry, it represents a valuable tool to accelerate the translation of novel discoveries from bench to bedside, potentially improving success rates in clinical trials and bringing new options to market faster.
Summary
Oncotelic Therapeutics (OTCQB: OTLC) announced that its 45%-owned joint venture, Sapu Nano, presented promising new data at the 2025 San Antonio Breast Cancer Symposium. The findings demonstrate that Sapu Nano's Deciparticle(TM) nanomedicine platform can successfully formulate a wide range of structurally diverse hydrophobic therapeutics into sub-20 nanometer nanoparticles suitable for intravenous (IV) delivery. This includes complex molecules like macrolide mTOR inhibitors, cyclic and linear peptides, ascomycin macrolactams, and polyketides. The company emphasized that this confirms the Deciparticle platform as a versatile and cGMP-ready delivery system, backed by ISO-5 manufacturing capabilities that support a rapid transition to Phase 1 clinical trial supply.
According to CEO Dr. Vuong Trieu, these results position Deciparticle as a modular engine capable of advancing multiple drug candidates across oncology, immunology, and peptide therapeutics. The first candidate emerging from this broader pipeline is Sapu003. Oncotelic Therapeutics is a clinical-stage biopharmaceutical company focused on developing innovative treatments for high-unmet-need cancers and rare pediatric diseases. The company's strategic position is bolstered by the extensive intellectual property of Dr. Trieu, who has filed over 150 patent applications and holds 39 issued U.S. patents. Beyond its internal programs, Oncotelic engages in licensing and codevelopment through joint ventures like GMP Bio, further expanding its therapeutic reach. For more details, investors can view the full press release via the provided link to the NetworkNewsWire platform.
This news was distributed by NetworkNewsWire (NNW), a specialized financial communications platform and part of the Dynamic Brand Portfolio at IBN. NNW provides comprehensive services including wire distribution, editorial syndication to over 5,000 outlets, press release enhancement, and social media distribution via IBN's extensive network. These services are designed to help companies like Oncotelic achieve significant brand awareness and reach a wide audience of investors and the general public. For ongoing updates, investors are directed to the company's newsroom or can opt into SMS alerts from NNW.
Source Statement
This curated news summary relied on content disributed by InvestorBrandNetwork (IBN). Read the original source here, Oncotelic's Nano Platform Shows Versatility in Delivering Complex Cancer Drugs
